BioNTech has brought British company Autolus Therapeutics on board in an intriguing $250 million upfront collaboration. The deal means BioNTech can use Autolus’ manufacturing and clinical site network across the U.K. to help efficiently develop BNT211 for pivotal trials in CLDN6+ tumors. Source: Fierce Biotech 8/2/2024